Prevalence of erectile dysfunction in Colombia, Ecuador, and Venezuela: a population-based study (DENSA)

Abstract

The purpose of this study was to estimate the prevalence of erectile dysfunction (ED) in Colombia, Ecuador, and Venezuela. A 49-item questionnaire was completed by 1946 men aged 40 years and older. The age-adjusted combined prevalence of minimal, moderate, and complete ED for all three countries was 53.4%, with 19.8% of all men reporting moderate to complete ED. Age was the variable most strongly linked to ED; the prevalence of complete ED increased markedly in men older than 79 y of age (31.9%) and 70 -79 y (17.2%) compared with men aged 40 -49 y (<3%). Several medical conditions, such as hypertension, benign prostatic hyperplasia, and diabetes, and the use of medications to treat these conditions were correlated with the prevalence of ED. This study corroborates earlier studies demonstrating that ED is very common, increases dramatically with age, and has multiple correlates, including some that are also risk factors for cardiovascular disease.

Tolerability and safety profile of sildenafil citrate (Viagra®) in Latin American patient populations

“…The most common concomitant illnesses were hypertension and diabetes mellitus, with the most common concomitant medications being antihypertensive drugs and antidiabetic drugs. This observation is consistent with the identification of hypertension and diabetes and associated drug treatments as significant correlates of ED in the epidemiological studies conducted in Brazil 8 and the northern countries of South America (Colombia, Ecuador, Venezuela), 6 as well as in other epidemiological studies. 9 Consistent with the identification of vascular disease as a risk factor for ED, 10 approximately 7% of all patients had underlying ischemic heart disease.…”

“…This history is consistent with the finding of disorders of the prostate as well as prostatic surgery as risk factors for ED among the sample populations from Brazil 8 and Colombia= Ecuador=Venezuela. 6 A past or present history of depression (current depression is shown in Table 2), a common comorbid condition and risk factor among middle-aged and elderly men with ED, 9 was documented in eight patients in the sildenafil group (2.9%) and seven in the placebo group (2.6%), with 17 (3%) of the total study patients taking antidepressant drugs concomitantly.…”

“…3 Indeed, the most common adverse events (AEs) associated with sildenafil in clinical trials conducted in the USA, the UK, and Europe were headache, flushing, dyspepsia, and nasal congestion, consistent with PDE5 inhibition in the systemic vasculature, the gastroesophageal sphincter, and the nasal mucosa; and transient visual symptoms, consistent with PDE6 inhibition in the retina. 4 The results of three double-blind, randomized, placebo-controlled, multicenter clinical evaluations of sildenafil in men with ED of various etiologies that were conducted in Brazil=Mexico, 5 and in the northern (Colombia, Ecuador, and Venezuela) 6 and southern regions of South America (Argentina, Peru, Chile, and Uruguay) 7 have been reported. The results of an analysis of the pooled safety data from these three studies are reported in this paper.…”

The prevalence of erectile dysfunction in men visiting outpatient clinics

“…4,8 ED is the most common sexual dysfunction among men aged above 40 years and its prevalence is between 41.7 and 53.4% in different countries of America. 2,3,5,9,10 In Europe, a study of 2869 Austrian men found a prevalence of 32.2% (all degrees of severity). 11 In Finland in 3787 men aged 50-75 years, the prevalence of ED was 76.5%.…”

Efficacy and safety of oral sildenafil citrate (Viagra®) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study

“…The prevalence was distributed by severity as follows: 33.6%, minimal ED; 16.2%, moderate ED; 3.6%, severe ED. 9 Currently recommended therapies for ED are limited and include intracorporal injection of vasoactive substances alone or in combination (papaverine, phentolamine, prostaglandin E1), 10 transurethral delivery of alprostadil, 11 vacuum devices, and prosthetic implantation. 12 All are associated with considerable limitations, including inconvenience, lack of spontaneity, poor toleration, and partial or restricted efficacy.…”